New Research Reveals Phelan-McDermid Syndrome Is Far More Common Than Previously Estimated, Prompting Calls for Universal Genetic Screening in Autism

Recent epidemiological and genetic investigations led by specialized researchers at the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai have fundamentally shifted the medical understanding of Phelan-McDermid syndrome (PMS). Published in the peer-reviewed journal Autism Research, the landmark study estimates that this rare genetic disorder affects approximately 1 in every 7,300 individuals. This revelation indicates a significantly larger patient population than historical figures suggested, implying that more than 45,000 people across the United States alone may be living with the condition, many of whom remain undiagnosed.

The findings arrive at a critical juncture in biomedical research. As precision medicine advances and targeted clinical trials progress toward potential disease-modifying therapies, healthcare providers, researchers, and patient advocacy groups are uniting behind an urgent mandate: expanding access to comprehensive genetic testing to identify hidden cases and connect patients with life-changing therapeutic interventions.

Understanding Phelan-McDermid Syndrome and Its Genetic Roots

Phelan-McDermid syndrome is a complex genetic disorder primarily caused by a microdeletion at the terminal end of chromosome 22q13 or, less frequently, by a mutation involving the SHANK3 gene located within that region. The SHANK3 gene plays a foundational role in neurodevelopment, encoding a master scaffolding protein localized at the postsynaptic density of excitatory synapses. This protein is essential for proper neuronal communication, synaptic plasticity, and the structural integrity of brain networks.

When the SHANK3 gene is disrupted, deleted, or mutated, it can trigger a cascade of neurodevelopmental impairments. Clinically, PMS is characterized by a broad spectrum of medical, intellectual, and behavioral challenges. Affected individuals often experience global developmental delay, severe speech impairments or complete absence of verbal communication, hypotonia (low muscle tone), motor dysfunctions, epilepsy, and gastrointestinal issues. Furthermore, a vast majority of individuals diagnosed with PMS also meet the diagnostic criteria for autism spectrum disorder (ASD). Current medical literature estimates that structural variations and mutations affecting the SHANK3 gene account for up to one percent of all diagnosed autism spectrum disorder cases globally.

Uncovering the True Prevalence: A Massive Data-Driven Analysis

For decades, the true prevalence of Phelan-McDermid syndrome remained obscured, largely because diagnostic criteria relied heavily on clinical presentation rather than routine genetic screening. To overcome these historical blind spots, researchers at Mount Sinai spearheaded a massive epidemiological effort, partnering with premier genetic testing laboratories, prominent academic medical centers, and large-scale autism research programs.

The investigative team conducted an exhaustive analysis of genetic data drawn from nearly 180,000 individuals with autism spectrum disorder who had undergone clinical or research-grade genetic testing. By synthesizing information from ten distinct, highly reliable data sources—including commercial and clinical laboratories such as GeneDx, Labcorp, and Ambry Genetics, alongside large-scale research initiatives like the SPARK research study, the Autism Sequencing Consortium, and several major U.S. children’s hospitals—the researchers constructed a robust statistical framework.

To arrive at the final prevalence estimate of 13.7 cases per 100,000 people (roughly 1 in 7,300), the team meticulously accounted for several confounding variables. These included undiagnosed cases within broader disability populations, technical limitations inherent in older or less comprehensive genetic testing panels, and a subset of individuals with Phelan-McDermid syndrome whose clinical presentations do not strictly overlap with autism spectrum disorder criteria, meaning they might otherwise escape detection by autism-focused screening protocols.

The Diagnostic Bottleneck: Systemic Barriers to Genetic Testing

The stark disparity between the historical baseline of known PMS cases and the newly calculated prevalence highlights systemic inefficiencies within the modern healthcare infrastructure. Tess Levy, MSc, an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the first author of the research paper, emphasized the institutional hurdles preventing families from securing accurate diagnoses.

"The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy explained. "Furthermore, families frequently face prohibitive insurance barriers, or they may receive legacy genetic tests that fail to evaluate the SHANK3 gene with sufficient resolution to detect subtle microdeletions or point mutations."

These diagnostic bottlenecks mean that tens of thousands of individuals traverse the healthcare and educational systems without understanding the underlying biological cause of their developmental delays. Without a genetic diagnosis, these patients miss out on specialized medical surveillance regimens tailored to the specific comorbidities associated with PMS, such as progressive motor decline, renal abnormalities, and psychiatric challenges.

The Imperative of Universal Genetic Screening in Autism

In light of the new prevalence data, the study’s senior leadership is advocating for a fundamental shift in pediatric and psychiatric evaluation standards. Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the study, argues that genetic literacy must become a cornerstone of modern neurodevelopmental care.

"We recommend that every child with autism undergo genetic testing, because knowledge is power," Dr. Buxbaum stated. "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."

Dr. Buxbaum’s perspective underscores a broader philosophical evolution in clinical medicine: moving away from purely behavioral symptom management toward precision medicine frameworks that target the root molecular and synaptic dysfunctions driving neurodevelopmental disorders.

Collaborative Support and Industry Momentum

The milestone study was made possible through dedicated financial and strategic backing from philanthropic and commercial stakeholders committed to rare disease research, specifically CureSHANK and Neuren Pharmaceuticals. This public-private collaboration reflects a shared recognition that closing the diagnostic gap is a prerequisite for advancing therapeutic pipelines.

Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, articulated the ethical and practical necessity driving industry involvement in epidemiological research.

"Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative," Dr. Groth noted. "Patients cannot benefit from these advances if they never receive a diagnosis."

Entering the Era of Precision Clinical Trials

The publication of this prevalence study coincides with a transformative phase in clinical research for Phelan-McDermid syndrome. For many years, therapeutic options for individuals with PMS were strictly palliative, focusing on physical therapy, speech therapy, and behavioral interventions to manage daily living challenges. However, a deeper scientific understanding of the SHANK3 pathway has unlocked entirely new therapeutic avenues.

Currently, several clinical trials are actively underway, evaluating precision medicine approaches designed to restore synaptic function, modulate glutamatergic signaling, or correct downstream molecular signaling cascades affected by the loss of the SHANK3 protein. As these investigational drugs move through Phase II and Phase III clinical development, the ability to rapidly identify and recruit eligible patients becomes paramount.

For affected families, securing a genetic diagnosis has evolved from an academic exercise into a gateway for tangible medical opportunities. A formal diagnosis links families to specialized multidisciplinary clinics, specialized patient registries, global support networks, and clinical trial enrollment opportunities that could potentially yield disease-modifying benefits.

Advocacy and the Future: Thinking Genetic First

Patient advocacy organizations have long championed the cause of expanded genetic testing, recognizing the profound isolation felt by families navigating rare neurodevelopmental disorders without clear answers. Geraldine Bliss, Board Chair of CureSHANK, praised the new findings for validating long-held community observations.

"This study confirms what many families, clinicians, and advocates have suspected for years," Bliss remarked. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."

To turn these research insights into actionable clinical change, CureSHANK continues to champion broad-based educational initiatives, including the Start Genetic global awareness campaign. This initiative encourages patients, families, primary care pediatricians, neurologists, and advocacy groups to adopt a "think genetic first" mindset when evaluating children presenting with developmental delays, intellectual disabilities, or autism spectrum disorder symptoms.

As the medical community digests the implications of Mount Sinai’s comprehensive study, the overarching message remains unequivocal. The scientific toolkit for treating genetic neurodevelopmental disorders is expanding at an unprecedented rate, but the promise of precision medicine can only be fulfilled for patients who have first been identified, diagnosed, and welcomed into the clinical research fold.